CLOs on the Move

Mitra Biotech

www.mitrabiotech.com

 
Mitra Biotech is the global leader in therapy selection in oncology. Mitra is led by an accomplished team of diagnostic and drug development professionals and is backed by world leading venture groups with long term commitment to Mitra’s vision in personalized cancer care.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Capital Genomix (US Headquarters)

Capital Genomix (US Headquarters) is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lexington Regional Health Center

At Lexington Regional Health Center, we are redefining health care. By embracing a truly patient-centered care model, we focus on you and your family`s needs. From urgent care and 24-hour emergency services, to radiology and physical therapy, we are here for you. Walking through our doors, you`ll feel right at home, because you are. Between detection and prevention, therapy and recovery, diagnosis and treatment; in the middle of it all, Lexington Regional is your health center.

Canadian Bacterial Diseases Network (CBDN)

Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.